二环戊基丁二酸酯 | 959-69-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 二环戊基丁二酸酯
• 英文名称: Bernsteinsaeure-dicyclopentylester
• 英文别名: succinic acid dicyclopentyl ester；Dicyclopentyl-succinat；Dicyclopentyl butanedioate
• CAS: 959-69-3
• 化学式: C₁₄H₂₂O₄
• 分子量: 254.326
• InChiKey: FWRFEGHSSFFLMN-UHFFFAOYSA-N

物化性质

• 沸点：
  345.0±15.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)
• 保留指数：
  1882

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2917190090

反应信息

• 作为产物：
  描述：

  丁二酸 、 环戊醇 在 硫酸 作用下， 生成 二环戊基丁二酸酯
  参考文献：
  名称：

  Cyclopentyl esters of polycarboxylic acids

  摘要：

  公开号：

  US02237729A1

文献信息

• Lactams substituted by cyclic succinates as inhibitors of a beta protein production
  申请人：——

  公开号：US20020137737A1

  公开（公告）日：2002-09-26

  This invention relates to novel lactams having the Formula (I): 1 to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

  这项发明涉及具有式(I)的新型内内酰胺，以及它们的药物组合物和使用方法。这些新型化合物抑制淀粉样前体蛋白的加工，更具体地说，抑制Aβ-肽的产生，从而防止淀粉样蛋白的神经沉积形成。更具体地说，本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病，如阿尔茨海默病和唐氏综合征。
• HYDROPHOBIC POLYSACCHARIDES WITH DIESTER- OR CARBONATE ESTER-CONTAINING LINKAGES HAVING ENHANCED DEGRADATION
  申请人：Swan Dale G.

  公开号：US20100316687A1

  公开（公告）日：2010-12-16

  Hydrophobic α(1→4)glucopyranose polymers with enhanced degradation properties are described. Between the α(1→4)glucopyranose polymeric portion and the hydrophobic portion exists a linker portion having a chemistry that facilitates degradation of the polymer. Diester and carbonate ester linker chemistries are exemplified. Biodegradable matrices can be formed from these polymers, and the matrices can be used for the preparation of implantable and injectable medical devices wherein the matrix is capable of degrading in vivo at an increased rate. Matrices including and capable of releasing a bioactive agent in vivo are also described.

  描述了具有增强降解性能的疏水性α(1→4)葡萄糖吡喃聚合物。在α(1→4)葡萄糖吡喃聚合物部分和疏水部分之间存在一个连接部分，其化学性质有助于聚合物的降解。举例说明了二酯和碳酸酯连接剂的化学性质。可以从这些聚合物形成可生物降解的基质，这些基质可用于制备可植入和可注射的医疗器械，其中基质能够在体内以增加的速率降解。还描述了包含并能够在体内释放生物活性物质的基质。
• Lactams substituted by cyclic succinates as inhibitors of Abeta protein production
  申请人：Olson E. Richard

  公开号：US20050261274A1

  公开（公告）日：2005-11-24

  This invention relates to novel lactams having the Formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有公式（I）的新型内酰胺，其制药组成物和使用方法。这些新化合物抑制淀粉样前体蛋白的处理，更具体地抑制Aβ-肽的产生，从而防止神经元中淀粉样蛋白的沉积形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经系统疾病的治疗，如阿尔茨海默病和唐氏综合症。
• Lactams substituted by cyclic succinates as inhibitors of A-beta protein production
  申请人：——

  公开号：US20030119815A1

  公开（公告）日：2003-06-26

  This invention relates to novel lactams having the Formula (I): 1 to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有公式(I)的新型内酰胺，以及它们的制药组合物和使用方法。这些新化合物抑制淀粉样前体蛋白的处理，更具体地抑制Aβ-肽的产生，从而防止神经元中出现淀粉样蛋白质的沉积。更具体地说，本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病，如阿尔茨海默病和唐氏综合症。
• LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION
  申请人：Olson E. Richard

  公开号：US20080103128A1

  公开（公告）日：2008-05-01

  This invention relates to novel lactams having the Formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有式(I)的新型内酰胺，它们的制药组合物和使用方法。这些新型化合物抑制淀粉样前体蛋白的加工，更具体地说，抑制Aβ肽的产生，从而防止神经沉积物的淀粉样蛋白形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经系统疾病的治疗，例如阿尔茨海默病和唐氏综合症。